1. Home
  2. LTBR vs LEXX Comparison

LTBR vs LEXX Comparison

Compare LTBR & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lightbridge Corporation

LTBR

Lightbridge Corporation

HOLD

Current Price

$13.75

Market Cap

578.2M

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.53

Market Cap

14.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTBR
LEXX
Founded
1992
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
578.2M
14.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LTBR
LEXX
Price
$13.75
$0.53
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
1.1M
1.4M
Earning Date
11-05-2025
01-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$705,923.00
Revenue This Year
N/A
$13.35
Revenue Next Year
N/A
$78.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
52.05
52 Week Low
$4.51
$0.46
52 Week High
$31.34
$2.43

Technical Indicators

Market Signals
Indicator
LTBR
LEXX
Relative Strength Index (RSI) 38.41 30.06
Support Level $12.95 $0.48
Resistance Level $15.19 $0.70
Average True Range (ATR) 1.07 0.12
MACD 0.04 -0.06
Stochastic Oscillator 14.65 6.73

Price Performance

Historical Comparison
LTBR
LEXX

About LTBR Lightbridge Corporation

Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: